A preliminary study on the application of N-acetylcysteine to evaluate the antioxidant-mediated effect of health effects caused by particulate matter

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0010531

Enrollment

Registered

2025-05-26

Start date

2023-02-02

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Study Drug (N-acetylcysteine) 1) Active ingredient: Acetylcysteine 2) Product name: Muteran Capsule 200 mg Placebo · 1) Appearance and dosage form: A hard capsule filled with white powder, wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults aged 19 years or older Non-smokers or former smokers who have abstained from smoking for at least one year Individuals who submit the results of a health screening conducted within the past year by the National Health Insurance Service (NHIS) or an equivalent examination; if such documentation is unavailable, participants will undergo tests corresponding to NHIS health screening items to confirm the absence of any uncontrolled acute or chronic diseases

Exclusion criteria

Exclusion criteria: - Individuals with clinically significant acute or chronic diseases requiring treatment, including but not limited to cardiovascular, cerebrovascular, endocrine, immune, respiratory, hepatobiliary, renal and urinary, neuropsychiatric, musculoskeletal, inflammatory, hematologic/oncologic, or gastrointestinal disorders - Individuals with contraindications or precautions for the study drug, including known hypersensitivity to this drug or its components, patients with gastric or duodenal ulcers, galactose intolerance, or lactase deficiency - Pregnant or breastfeeding women - Individuals deemed by the investigator to be unsuitable for participation in this study

Design outcomes

Primary

Measure	Time frame
Cytokines: IL-6, IL-8, IL-10, IL-1ß (interleukin-1 beta), TNF-a (tumor necrosis factor-alpha), IFN-? (interferon-gamma);Exhaled nitric oxide (FeNO);Blood pressure: Systolic blood pressure (SBP) and diastolic blood pressure (DBP);Pulmonary function test: FEV1 (Forced Expiratory Volume in 1 second), FVC (Forced Vital Capacity), and FEV1/FVC ratio	—

Secondary

Measure	Time frame
Heart Rate	—

Countries

Korea, Republic of

Contacts

Public ContactHwan-Cheol Kim

Inha University Hospital

cheol17@hanmail.net+82-32-890-3216

Outcome results